HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 341 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Making the most of your ‘eureka’ moment: getting from the science... September 22, 2021 Working Together to Choose a Cancer Treatment Plan: A Caregiver’s Perspective June 16, 2022 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 Nurse With Terminal Breast Cancer Spends Her Days Caring For Pediatric... April 14, 2020 Load more HOT NEWS New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast... New on NCI’s Websites for November 2024 Truck Driver Saves People From Bus Fire On Christmas Eve Five Questions with…Fred.
